Stories Tagged as
Why Bill Ackman sees activist investing as a moral crusade
For the Pershing Square Capital Management CEO, activist investing is just as much a moral calling as it is a lucrative one
Valeant Pharmaceuticals and the dark side of capitalism
Investors' demands for more profits left patients with the choice to pay up or die.
How to oust a corporate board member
Toppling Yahoo's entire board or removing one Valeant board member can be hard.
Valeant's story: a cautionary tale
The company's CEO stepped down on Monday
Valeant swears off aggressive drug pricing strategy
Valeant and a handful other firms may ditch a model that's come under fire.
Valeant: how aggressively can a drug company sell
Valeant is under scrutiny for its business practices.